Contribute Try STAT+ Today

The Nobel Prize and biotechnology have been intertwined for decades.

Though the prizes in the scientific field always go to basic researchers, scientists have won the Nobel Prize for some obviously translatable discoveries. Some have won for discovering specific treatments, like penicillin and artemisinin and insulin. They’ve won prizes for discovering the underlying causes of a disease, like the HPV and HIV viruses. One team of scientists even won a Nobel Prize for putting those two things together. Gertrude Elion and two of her colleagues won the prize in 1988 for figuring out that rational drug design — designing drugs based on a specific target — could be a thing; she used that technique to discover Daraprim, AZT, and acyclovir.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Excellent piece. Always suspected that Nobel prizes were awarded post hoc after R&D conducted by companies established the actual value of the discovery for patients. It would be interesting to provide actual dates between the initial publication of the seminal paper(d) and the FDA approval. Looking just at immuno-oncology and hepatitis C, it looks like a 25-30 year lag. Do you know of a paper that looked into this lag between first publication / first drug approved ?

Comments are closed.